MiR-148a dependent apoptosis of bladder cancer cells is mediated in part by the epigenetic modifier DNMT1

Molecular Carcinogenesis

Volumn 55, Issue 5, 2016, Pages 757-767

  Lombard, Alan P ^a,b,c   Mooso, Benjamin A ^c   Libertini, Stephen J ^a,c   Lim, Rebecca M ^a   Nakagawa, Rachel M ^a   Vidallo, Kathleen D ^a   Costanzo, Nicole C ^a   Ghosh, Paramita M ^b,c   Mudryj, Maria ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

Author keywords

Apoptosis; Bladder cancer; Cell cycle; Cisplatin; DNA methyltransferase (DNMT1); Doxorubicin; MiR 148a

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DNA METHYLTRANSFERASE 1; DOXORUBICIN; MICRORNA; MICRORNA 148A; UNCLASSIFIED DRUG; DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE 1; MIRN148 MICRORNA, HUMAN;

APOPTOSIS; ARTICLE; BLADDER CANCER CELL LINE; BLADDER CARCINOMA; BLADDER UROTHELIAL CELL CARCINOMA; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; EPIGENETICS; GENE OVEREXPRESSION; IN VITRO STUDY; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; BLADDER TUMOR; CELL SURVIVAL; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; HUMAN; PATHOLOGY; TUMOR CELL LINE; UROTHELIUM;

APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DOWN-REGULATION; DOXORUBICIN; DRUG SYNERGISM; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84927145627     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22319     Document Type: Article

References (32)

1. Yafi FA, North S, Kassouf W. First- and second-line therapy for metastatic urothelial carcinoma of the bladder. Curr Oncol 2011; 18:e25-e34.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90.
3. Amsellem-Ouazana D, Bieche I, Tozlu S, Botto H, Debre B, Lidereau R. Gene expression profiling of ERBB receptors and ligands in human transitional cell carcinoma of the bladder. J Urol 2006; 175:1127-1132.
4. Pliarchopoulou K, Laschos K, Pectasides D. Current chemotherapeutic options for the treatment of advanced bladder cancer: A review. Urol Oncol 2013; 31:294-302.
5. Kim JJ. Recent advances in treatment of advanced urothelial carcinoma. Curr Urol Rep 2012; 13:147-152.
6. Verdoorn BP, Kessler ER, Flaig TW. Targeted therapy in advanced urothelial carcinoma. Oncology (Williston Park) 2013; 27:219-226.
7. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: Are the answers in sight?. Nat Rev Genet 2008; 9:102-114.
8. Song T, Zhang X, Zhang L, et al. MiR-708 promotes the development of bladder carcinoma via direct repression of Caspase-2. J Cancer Res Clin Oncol 2013; 139:1189-1198.
9. Hirata H, Ueno K, Shahryari V, et al. Oncogenic miRNA-182-5p targets Smad4 and RECK in human bladder cancer. PLoS One 2012; 7:e51056.
10. Vinall RL, Ripoll AZ, Wang S, Pan CX, deVere White RW. MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status. Int J Cancer 2012; 130:2526-2538.
11. Xu X, Chen H, Lin Y, et al. MicroRNA-409-3p inhibits migration and invasion of bladder cancer cells via targeting c-Met. Mol Cells 2013; 36:62-68.
12. Li J, Song Y, Wang Y, Luo J, Yu W. MicroRNA-148a suppresses epithelial-to-mesenchymal transition by targeting ROCK1 in non-small cell lung cancer cells. Mol Cell Biochem 2013; 380:277-282.
13. Zheng B, Liang L, Wang C, et al. MicroRNA-148a suppresses tumor cell invasion and metastasis by downregulating ROCK1 in gastric cancer. Clin Cancer Res 2011; 17:7574-7583.
14. Yan H, Dong X, Zhong X, et al. Inhibitions of epithelial to mesenchymal transition and cancer stem cells-like properties are involved in miR-148a-mediated anti-metastasis of hepatocellular carcinoma. Mol Carcinog 2013; 53:960-969.
15. Xu X, Fan Z, Kang L, et al. Hepatitis B virus X protein represses miRNA-148a to enhance tumorigenesis. J Clin Invest 2013; 123:630-645.
16. Zhang R, Li M, Zang W, et al. MiR-148a regulates the growth and apoptosis in pancreatic cancer by targeting CCKBR and Bcl -2. Tumour Biol 2013; 35:837-844.
17. Zhang H, Li Y, Huang Q, et al. MiR-148a promotes apoptosis by targeting Bcl-2 in colorectal cancer. Cell Death Differ 2011; 18:1702-1710.
18. Lujambio A, Calin GA, Villanueva A, et al. A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A 2008; 105:13556-13561.
19. Shivapurkar N, Weiner LM, Marshall JL, et al. Recurrence of Early Stage Colon Cancer Predicted by Expression Pattern of Circulating microRNAs. PLoS One 2014; 9:84686.
20. Aydogdu E, Katchy A, Tsouko E, et al. MicroRNA-regulated gene networks during mammary cell differentiation are associated with breast cancer. Carcinogenesis 2012; 33:1502-1511.
21. Fujita Y, Kojima K, Ohhashi R, et al. MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression. J Biol Chem 2010; 285:19076-19084.
22. Kar S, Deb M, Sengupta D, et al. An insight into the various regulatory mechanisms modulating human DNA methyltransferase 1 stability and function. Epigenetics 2012; 7:994-1007.
23. Qin W, Leonhardt H, Pichler G. Regulation of DNA methyltransferase 1 by interactions and modifications. Nucleus 2011; 2:392-402.
24. Singh V, Sharma P, Capalash N. DNA methyltransferase-1 inhibitors as epigenetic therapy for cancer. Curr Cancer Drug Targets 2013; 13:379-399.
25. Wu CT, Wu CF, Lu CH, et al. Expression and function role of DNA methyltransferase 1 in human bladder cancer. Cancer 2011; 117:5221-5233.
26. Zhang S, Zeng F, Peng S, Zhu C, Li H, Wang L. Effects on biological behavior of bladder carcinoma T24 cells via silencing DNMT1 and/or DNMT3b with shRNA in vitro. J Huazhong Univ Sci Technolog Med Sci 2009; 29:215-219.
27. Ting AH, Jair KW, Schuebel KE, Baylin SB. Differential requirement for DNA methyltransferase 1 in maintaining human cancer cell gene promoter hypermethylation. Cancer Res 2006; 66:729-735.
28. Gailhouste L, Gomez-Santos L, Hagiwara K, et al. MiR-148a plays a pivotal role in the liver by promoting the hepatospecific phenotype and suppressing the invasiveness of transformed cells. Hepatology 2013; 58:1153-1165.
29. Zhu A, Xia J, Zuo J, et al. MicroRNA-148a is silenced by hypermethylation and interacts with DNA methyltransferase 1 in gastric cancer. Med Oncol 2012; 29:2701-2709.
30. Xiang Y, Ma N, Wang D, et al. MiR-152 and miR -185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: A novel epigenetic therapy independent of decitabine. Oncogene 2013; 33:378-386.
31. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144:646-674.
32. Dhawan D, Ramos-Vara JA, Hahn NM, et al. DNMT1: An emerging target in the treatment of invasive urinary bladder cancer. Urol Oncol 2012; 31:1761-1769.